XNCR News and Press, Xencor Inc. From 09/03/25

2025-09-03 15:14:58 ET Shares of infectious disease and oncology concern Vir Biotechnology, Inc. ( VIR ) are down ~65% since enthusiasm generated from initial T cell engager data sparked a rally in January 2025. Its sole remaining infectious disease asset, a combination of tobevibar...

2025-09-03 15:14:48 ET More on Erasca, Xencor, etc. Candel Therapeutics announces $15M in direct offering Incyte granted FDA label expansion for lymphoma therapy Monjuvi Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca ...

2025-08-11 06:25:01 ET More on Sarepta Therapeutics, Capricor Therapeutics, Inc., etc. Replimune Group: The Prospects For FDA Approval After Rejection Sarepta Therapeutics: Beaten Down, But Not Out Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program ...

2025-08-06 17:23:00 ET More on Xencor Incyte granted FDA label expansion for lymphoma therapy Monjuvi Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial information for Xencor Read the full article on Seeking...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "...

Kyndryl Holdings Inc. (KD) is expected to report $0.25 for Q1 2026 Bruker Corporation (BRKR) is expected to report $0.33 for Q2 2025 Vornado Realty Trust (VNO) is expected to report $0.53 for Q2 2025 Diamondback Energy Inc. (FANG) is expected to report $2.63 for Q2 2025 Freightcar...

Xencor Inc. (XNCR) is expected to report $-0.78 for Q2 2025

2025-08-03 18:45:28 ET Xencor, Inc. (XNCR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.69%. The average open to low on the day of earnings was -4.67%. The average open to close on ...

2025-08-03 18:40:28 ET Xencor, Inc. (XNCR) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in XNCR stock price following earnings has averaged ±3.57% , with a median of 2.71%. The sin...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell b...